Related Experiment Video
Updated: May 18, 2026

Determining Pain Detection and Tolerance Thresholds Using an Integrated, Multi-Modal Pain Task Battery
Published on: April 14, 2016
Compliance, analgesic use and side-effect protection within a German cohort of the TEAM trial
Michaela Bossart1, Meike Becker, Peyman Hadji
1University Hospital Freiburg, Freiburg, Germany.
Background:
Compliance is an essential aspect for the success of any medical intervention. Adverse events (AEs) contribute significantly to non-compliance with endocrine treatment. The Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial compared five years of adjuvant exemestane therapy with the sequence of tamoxifen followed by exemestane.
Patients And Methods:
A retrospective analysis of the German cohort of TEAM was conducted to determine the effects of prior tamoxifen on the tolerability profile of exemestane in both treatment arms.
Results:
Fracture incidence was significantly higher during the first 30 months of exemestane versus the 30 months of exemestane following tamoxifen for 2-3 years; however, the incidence of AEs was not significantly different. With regard to compliance, the use of analgesics did not influence overall or disease-free survival (DFS) nor the incidence of distant recurrence in both treatment groups.
Conclusion:
Tamoxifen has a boneprotective effect when applied before exemestane treatment. Intake of analgesics (or pain medication) does not influence compliance or treatment outcome.
Related Concept Videos
Bioavailability Study Design: Healthy Subjects Versus Patients
Therapeutic Drug Monitoring: Affecting Factors
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Analgesia and Pain Management
Bioequivalence studies: Biowaivers